About Profound Bio
Profound Bio is a company based in Woodinville (United States) founded in 2018 was acquired by Genmab in April 2024.. Profound Bio has raised $237 million across 3 funding rounds from investors including Genmab, T. Rowe Price and Citadel. Profound Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Woodinville, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Profoundbio Us Co
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Profound Bio
Profound Bio has successfully raised a total of $237M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $112 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $112.0M
-
First Round
First Round
(12 Jul 2021)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Series B - Profound Bio | Valuation | Nextech Invest , Janus Henderson Investors | |
| Jun, 2022 | Amount | Series A - Profound Bio | Valuation |
investors |
|
| Jul, 2021 | Amount | Series A - Profound Bio | Valuation | Lilly Asia Ventures , LYFE Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Profound Bio
Profound Bio has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Genmab, T. Rowe Price and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Profound Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Profound Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Profound Bio Comparisons
Competitors of Profound Bio
Profound Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Profound Bio
Frequently Asked Questions about Profound Bio
When was Profound Bio founded?
Profound Bio was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is Profound Bio located?
Profound Bio is headquartered in Woodinville, United States. It is registered at Woodinville, Washington, United States.
Who is the current CEO of Profound Bio?
Baiteng Zhao is the current CEO of Profound Bio.
Is Profound Bio a funded company?
Profound Bio is a funded company, having raised a total of $237M across 3 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Jul 12, 2021.
What does Profound Bio do?
Profound Bio was founded in 2018 and is based in Woodinville, United States. Operations focus on the biotechnology sector, where novel therapies for cancer treatment are developed. Emphasis is placed on chemistry, manufacturing, and controls (CMC) for antibody-drug conjugates. These conjugates are engineered to target and kill tumor cells, promote cell rejuvenation, stimulate collagen production, and inhibit collagen degradation processes.
Who are the top competitors of Profound Bio?
Profound Bio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Who are Profound Bio's investors?
Profound Bio has 21 investors. Key investors include Genmab, T. Rowe Price, Citadel, Orbimed, and Janus Henderson Investors.